Analyser af undergrupper viste, at den gavnlige virkning var mest udtalt hos patienter, som snarere hørte til i gruppen af patienter med hypertriglyceridæmi og blandet dyslipidæmi end i gruppen med hyperkolesterolæmi.
Patients were selected on the basis of non-HDL cholesterol with an acceptance level ≥ 5.2 mmol/ l without specifying levels of LDL- and HDL-cholesterol and triglycerides), Subgroup analysis showed that benefit was most pronounced in the patients who probably fitted more in the patients with hypertriglyceridaemia and mixed dyslipidaemia than in those with hypercholesterolemia.